Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

被引:1219
|
作者
Tartaglia, M [1 ]
Mehler, EL
Goldberg, R
Zampino, G
Brunner, HG
Kremer, H
van der Burgt, I
Crosby, AH
Ion, A
Jeffery, S
Kalidas, K
Patton, MA
Kucherlapati, RS
Gelb, BD
机构
[1] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA
[3] Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA
[4] Ist Super Sanita, Lab Metab & Biochim Patol, I-00161 Rome, Italy
[5] Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA
[6] Univ Cattolica Sacro Cuore, Ist Clin Pediat, Rome, Italy
[7] Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands
[8] Univ London St Georges Hosp, Sch Med, Dept Med Genet, London SW17 0RE, England
基金
美国国家卫生研究院;
关键词
D O I
10.1038/ng772
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy)(1,2). Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000-2,500 live births. it has been mapped to a 5-cM region (N-SH2) on chromosome 12q24.1, and genetic heterogeneity has also been documented(3-6). Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 50 条
  • [21] Mutations in the PTPN11 cause cardiac defects associated with Noonan syndrome
    Kamisago, M
    Hirayama, K
    Kato, T
    Imamura, S
    Joh, K
    Ando, M
    Takao, A
    Momma, K
    Matsuoka, R
    CIRCULATION, 2002, 106 (19) : 289 - 289
  • [22] PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome
    Kosaki, K
    Suzuki, T
    Muroya, K
    Hasegawa, T
    Sato, S
    Matsuo, N
    Kosaki, R
    Nagai, T
    Hasegawa, Y
    Ogata, T
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08): : 3529 - 3533
  • [23] Mutations in the protein tyrosine kinase gene, PTPN11, cause Noonan Syndrome (vol 29, pg 465, 2001)
    Tartaglia, M
    Mehler, EL
    Goldberg, R
    Zampino, G
    Brunner, HG
    Kremer, H
    van der Burgt, I
    Crosby, AH
    Ion, A
    Jeffery, S
    Kalidas, K
    Patton, MA
    Kucherlapati, RS
    Gelb, B
    NATURE GENETICS, 2001, 29 (04) : 491 - 491
  • [24] PTPN11 (protein tyrosine phosphatase, nonreceptor type-11) mutations and response to growth hormone therapy in children with Noonan syndrome
    Ferreira, LV
    Souza, SAL
    Arnhold, IJP
    Mendonca, BB
    Jorge, AAL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09): : 5156 - 5160
  • [25] Noonan syndrome: Severe phenotype and PTPN11 mutations
    Carrasco Salas, Pilar
    Gomez-Molina, Gertrudis
    Carreto-Alba, PAxedes
    Granell-Escobar, Reyes
    Vazquez-Rico, Ignacio
    Leon-Justel, Antonio
    MEDICINA CLINICA, 2019, 152 (02): : 62 - 64
  • [26] Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)
    Liu, Wei
    Yu, Bing
    Xu, Gang
    Xu, Wei-Ren
    Loh, Mignon L.
    Tang, Li-Da
    Qu, Cheng-Kui
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (18) : 7212 - 7221
  • [27] PTPN11 mutations in Noonan syndrome and hydrops fetalis.
    Jones, JR
    Wood, TC
    Whalen, MA
    Haddock-Bolt, C
    Seaver, LH
    Schroer, RJ
    Rogers, RC
    Everman, DE
    Friez, MJ
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 579 - 579
  • [28] Genomic Duplication of PTPN11 Is an Uncommon Cause of Noonan Syndrome
    Graham, John M., Jr.
    Kramer, Nancy
    Bejjani, Bassem A.
    Thiel, Christian T.
    Carta, Claudio
    Neri, Giovanni
    Tartaglia, Marco
    Zenker, Martin
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2009, 149A (10) : 2122 - 2128
  • [29] Analysis of PTPN11 mutations in Japanese patients with Noonan syndrome
    Namba, N
    Ogura, E
    Morishima, T
    Seino, Y
    Tanaka, H
    PEDIATRIC RESEARCH, 2004, 55 (04) : 160A - 160A
  • [30] Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling
    Uhlén, P
    Burch, PM
    Zito, CL
    Estrada, M
    Ehrlich, BE
    Bennett, AM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) : 2160 - 2165